Adaptive immune responses associated with breast cancer relapse

Archivum Immunologiae et Therapiae Experimentalis

Volumn 60, Issue 5, 2012, Pages 345-350

  Payne, Kyle K ^a   Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Breast cancer stem cells; Her 2 neu; IFN ; Immunoediting; Relapse; Tumor escape

Indexed keywords

ALPHA INTERFERON RECEPTOR; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; TRASTUZUMAB;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DNA METHYLATION; DOWN REGULATION; DRUG EFFICACY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOMODULATION; INTRADUCTAL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR ESCAPE; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INTERFERON-GAMMA; MAMMARY NEOPLASMS, ANIMAL; MICE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; RATS; RECURRENCE;

EID: 84866601456     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-012-0185-y     Document Type: Review

References (62)

1. Beatty GL, Paterson Y (2000) IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 165:5502-5508
2. Benson JR, Jatoi I, Keisch M et al (2009) Early breast cancer. Lancet 373:1463-1479
3. Berner V, Liu H, Zhou Q et al (2007) IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 13:354-360 (Pubitemid 46376686)
4. Blanco JC, Contursi C, Salkowski CA et al (2000) Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med 191:2131-2144 (Pubitemid 30416360)
5. Bui JD, Schreiber RD (2007) Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19:203-208 (Pubitemid 46356963)
6. Cicalese A, Bonizzi G, Pasi CE et al (2009) The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138:1083-1095
7. Connett JM, Hunt SR, Hickerson SM et al (2003) Localization of IFN-gamma-activated Stat1 and IFN regulatory factors 1 and 2in breast cancer cells. J Interf Cytokine Res 23:621-630 (Pubitemid 37452902)
8. Czerniecki BJ, Koski GK, Koldovsky U et al (2007) Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67:1842-1852 (Pubitemid 46383411)
9. Daniel N, Meyer-Morse EK, Bergsland K et al (2003) Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197:1017-1028
10. Doherty GM, Boucher L, Sorenson K et al (2001) Interferon regulatory factor expression in human breast cancer. Ann Surg 233:623-629 (Pubitemid 32378645)
11. Dumont N, Wilson MB, Crawford YG et al (2008) Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 105:14867-14872
12. Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998 (Pubitemid 35363648)
13. Dunn GP, Sheehan KC, Old LJ et al (2005) IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 65:3447-3453 (Pubitemid 40524631)
14. Farrar JD, Katz KH, Windsor J et al (1999) Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol 1162:2842-2849 (Pubitemid 29309310)
15. Ginestier C, Liu S, Diebel ME et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120:485-497
16. Hall VL, Subleski J, Back TC et al (2007) Friend or foe+ IFNgamma mediates pro-metastatic gene expression in the tumor microenvironment. J Immunol 178(48):34
17. Hallermalm K, Seki K, De Geer A et al (2008) Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 180:3766-3774
18. Harada H, Willison K, Sakakibara J et al (1990) Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell 63:303-312
19. Hida S, Ogasawara K, Sato K et al (2000) CD8+ T cell mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-α/β signalling. Immunity 13:643-655
20. Holmes JP, Gates JD, Benavides LC et al (2008) Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 113:1666-1675
21. Hoque A, Sneige N, Sahin AA et al (2002) Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 11:587-590 (Pubitemid 34615167)
22. Houssami N, Macaskill P, Balleine RL et al (2011) HER2discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat 129:659-674
23. Iliopoulos D, Hirsch HA, Wang G et al (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with nonstem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 108:1397-1402
24. Jesse TL, LaChance R, Iademarco MF et al (1998) Interferon regulatory factor-2 is a transcriptional activator in muscle where it regulates expression of vascular cell adhesion molecule-1. J Cell Biol 140:1265-1276 (Pubitemid 28128884)
25. Joung JY, Cho KS, Kim JE et al (2010) Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. J Surg Oncol 101:145-148
26. Kang JH, Kim SJ, Noh DY et al (2001) Methylation in the p53promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 81:573-579 (Pubitemid 32298803)
27. Kmieciak M, Knutson KL, Dumur CI et al (2007) HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 37:675-685 (Pubitemid 46916934)
28. Kmieciak M, Payne KK, Idowu MO et al (2011) Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. J Transl Med 9:35
29. Koeppel M, van Heeringen SJ, Smeenk L et al (2009) The novel p53 target gene IRF2BP2 participates in cell survival during the p53stress response. Nucleic Acids Res 37:322-335
30. Kominsky SL, Hobeika AC, Lake FA et al (2000) Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res 60:3904-3908 (Pubitemid 32204585)
31. Korkaya H, Wicha MS (2009) HER-2, Notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 15:1845-1847
32. Korkaya H, Paulson A, Iovino F et al (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27:6120-6130
33. Korkaya H, Liu S, Wicha MS (2011) Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res 17:6125-6129
34. Kusumbe AP, Bapat SA (2009) Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69:9245-9253
35. Levina V, Marrangoni AM, De Marco R et al (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3:e3077
36. Liu K, Caldwell SA, Greeneltch KM et al (2006) CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol 176:3374-3382 (Pubitemid 43363984)
37. Ljunggren HG (2008) Cancer immunosurveillance: NKG2D breaks cover. Immunity 28:492-494
38. Magnifico A, Albano L, Campaner S et al (2009) Tumour-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are trastuzumab sensitive. Clin Cancer Res 15:2010-2021
39. Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715 (Pubitemid 351636299)
40. Matkowski R, Gisterek I, Halon A et al (2009) The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res 29:2445-2451
41. Nicholaou T, Chen W, Davis ID et al (2011) Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIXTM. Cancer Immunol Immunother 60:1625-1637
42. Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to trastuzumab in breast cancer. Clin Cancer Res 15:7479-7491
43. Rattigan Y, Hsu JM, Mishra PJ et al (2010) Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp Cell Res 316:3417-3424
44. Reim F, Dombrowski Y, Ritter C et al (2009) Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res 69:8058-8066
45. Romieu-Mourez R, François M, Abate A et al (2010) Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. Cancer Res 70:7742-7747
46. Rosenberg SA, Sherry RM, Morton KE et al (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175:6169-6176 (Pubitemid 41508105)
47. Roses RE, Paulson EC, Sharma A et al (2009) HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 18:1386-1389
48. Santinelli A, Pisa E, Stramazzotti D et al (2008) HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 122:999-1004 (Pubitemid 351213996)
49. Santisteban M, Reiman JM, Asiedu MK et al (2009) Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 69:2887-2895
50. Sato T, Onai N, Yoshihara H et al (2009) Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med 15:696-700
51. Sauer KA, Maxeiner JH, Karwot R et al (2008) Immunosurveillance of lung melanoma metastasis in EBI-3-deficient mice mediated by CD8+ T cells. J Immunol 181:6148-6157
52. Sheu BC, Kuo WH, Chen RJ et al (2008) Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. Breast 17:604-610
53. Silva HC, Garcao F, Coutinho EC et al (2006) Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells. Neoplasma 53:538-543 (Pubitemid 46133516)
54. Singh R, Paterson Y (2007) Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res 67:1887-1892 (Pubitemid 46424202)
55. Taniguchi T, Ogasawara K, Takaoka A et al (2001) IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655 (Pubitemid 32368048)
56. Terada K, Okochi-Takada E, Akashi-Tanaka S et al (2009) Association between frequent CpG island methylation and HER2amplification in human breast cancers. Carcinogenesis 30:466-471
57. Vesuna F, Lisok A, Kimble B et al (2009) Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 11:1318-1328
58. Watanabe N, Sakakibara J, Hovanessian A et al (1991) Activation of IFN-β promoter element by IRF-1 requires a post-translational event in addition to IRF-1 synthesis. Nucleic Acids Res 19:4421-4428 (Pubitemid 21912819)
59. Worschech A, Kmieciak M, Knutson KL et al (2008) Signatures associated with rejection or recurrence in HER-2/neu positive mammary tumors. Cancer Res 68:2436-2446 (Pubitemid 351521819)
60. Wu TH, Schreiber K, Arina A et al (2011) Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun 11:2
61. Xie G, Yao Q, Liu Y et al (2012) IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int J Oncol 40:1171-1179
62. Yim JH, Ro SH, Lowney JK et al (2003) The role of interferon regulatory factor-1 and interferon regulatory factor-2 in IFNgamma growth inhibition of human breast carcinoma cell lines. J Interf Cytokine Res 23:501-511 (Pubitemid 37130073)